Certified Principal Investigator (CPI®) — Questions and Answers

Question 1: Under 21 CFR 312.32, within what timeframe must a non-fatal, non-life-threatening unexpected serious adverse drug reaction be reported to the FDA?

7 calendar days
60 calendar days
15 calendar days (Correct answer)
30 calendar days

Correct answer: 15 calendar days

Non-fatal, non-life-threatening unexpected serious adverse drug reactions must be reported to the FDA as an IND safety report within 15 calendar days.

Question 2: What is the primary reason for maintaining accurate and contemporaneous source records in a clinical trial?

To provide a verifiable audit trail that ensures data integrity and supports patient safety oversight (Correct answer)
To fulfill academic publication requirements
To satisfy sponsor billing requirements
To minimize the number of monitoring visits required

Correct answer: To provide a verifiable audit trail that ensures data integrity and supports patient safety oversight

Contemporaneous source records create an auditable trail that allows verification of safety data, supports regulatory review, and ensures accountability.

Question 3: What does residual risk mean in CPI practice?

Risk affecting waste materials
Initial risk before assessment
Budget overrun risk
Risk remaining after all controls are implemented (Correct answer)

Correct answer: Risk remaining after all controls are implemented

Residual risk is the level remaining after practical controls are applied. Some is usually accepted as eliminating all risk is rarely feasible.

Question 4: When computing a 95% confidence interval for a treatment effect, which statement is correct?

If the study were repeated many times, 95% of such intervals would contain the true effect (Correct answer)
The p-value for the treatment effect is exactly 0.05
There is a 95% probability the true effect lies within this specific interval
The confidence interval tells us the clinical significance of the result

Correct answer: If the study were repeated many times, 95% of such intervals would contain the true effect

A 95% CI means that 95% of intervals constructed this way across repeated studies would capture the true parameter — it is a frequentist property of the method, not of this interval.

Question 5: An electronic data capture (EDC) system audit trail is important in clinical trials because it:

Replaces the need for source document verification
Allows sponsors to delete unfavorable data entries
Provides a chronological record of all data changes, who made them, and when (Correct answer)
Is only required for Phase III trials

Correct answer: Provides a chronological record of all data changes, who made them, and when

Audit trails document the history of data entry and changes to ensure data integrity and allow reconstruction of the sequence of events.

Question 6: Which of the following is NOT a required element of informed consent under 21 CFR Part 50?

Statement describing confidentiality of records
Description of reasonably foreseeable risks
Subject's insurance coverage details (Correct answer)
Statement that participation is voluntary

Correct answer: Subject's insurance coverage details

Insurance coverage details are not a federally mandated element of informed consent; the required elements focus on risks, benefits, alternatives, confidentiality, and voluntary participation.

Question 7: When a study is placed on clinical hold by the FDA due to safety concerns, investigators must:

Continue existing participant treatment until the hold is resolved
Request IRB permission to continue enrollment while the hold is reviewed
Immediately stop enrolling new subjects and follow FDA instructions regarding current participants (Correct answer)
Notify only enrolled participants but continue screening new candidates

Correct answer: Immediately stop enrolling new subjects and follow FDA instructions regarding current participants

An FDA clinical hold requires immediate cessation of enrollment and compliance with any FDA-directed actions for currently enrolled participants.

Question 8: Which document outlines the globally accepted ethical principles for conducting research involving human subjects that emerged from the Nuremberg trials?

Common Rule (45 CFR 46)
Declaration of Helsinki
Nuremberg Code (Correct answer)
Belmont Report

Correct answer: Nuremberg Code

The Nuremberg Code (1947) established foundational ethical principles for human experimentation, including voluntary consent, after Nazi war crimes.

Question 9: A participant in an oncology trial develops grade 3 thrombocytopenia (platelets 25,000/µL). Per ICH E6 GCP guidelines, what is the investigator's primary obligation regarding this event?

Report only to the IRB and not the sponsor
Assess causality, treat the participant, and report as a serious adverse event to the sponsor (Correct answer)
Discontinue all study medications immediately without assessment
Continue the study drug with dose reduction and observe

Correct answer: Assess causality, treat the participant, and report as a serious adverse event to the sponsor

Grade 3 thrombocytopenia is serious; the investigator must ensure participant safety, assess causality, and report the SAE to the sponsor within required timeframes per ICH E6.

Question 10: A sponsor-investigator discovers that a protocol deviation occurred due to a misunderstanding of the protocol. What is the FIRST required action?

Document the deviation and notify the IRB promptly (Correct answer)
Amend the informed consent form
Terminate the participant from the study
Notify FDA before any other action

Correct answer: Document the deviation and notify the IRB promptly

Protocol deviations must be promptly documented and reported to the IRB, which determines whether further regulatory reporting is necessary.

Question 11: When a natural disaster disrupts a clinical trial site and participants cannot be reached for scheduled study visits, the investigator's primary obligation is to:

Terminate all participants due to missed visits
Continue data collection remotely without documenting the disruption
Wait for sponsor guidance before taking any action
Ensure participant safety and document the force majeure event, notifying the IRB and sponsor (Correct answer)

Correct answer: Ensure participant safety and document the force majeure event, notifying the IRB and sponsor

In force majeure events, participant safety takes priority; the investigator must document the disruption and notify oversight bodies per protocol and regulatory requirements.

Question 12: What does residual risk mean in CPI practice?

Budget overrun risk
Risk remaining after all controls are implemented (Correct answer)
Risk affecting waste materials
Initial risk before assessment

Correct answer: Risk remaining after all controls are implemented

Residual risk is the level remaining after practical controls are applied. Some is usually accepted as eliminating all risk is rarely feasible.

Question 13: A participant in a blinded clinical trial requires emergency surgery and the surgeon needs to know the study drug. What is the correct action?

Discontinue the participant without unblinding
Use the emergency unblinding procedure to reveal the participant's treatment assignment (Correct answer)
Treat the participant as if on placebo until the blind can be broken formally
Contact the sponsor's medical monitor first

Correct answer: Use the emergency unblinding procedure to reveal the participant's treatment assignment

Emergency unblinding procedures exist to protect participant safety; the investigator should use the defined emergency unblinding process immediately.

Question 14: A female subject of childbearing potential is being screened for a clinical trial involving a teratogenic investigational drug. Which pregnancy test result is required before enrollment?

A negative serum or urine pregnancy test within the timeframe specified in the protocol (Correct answer)
A verbal confirmation from the subject that she is not pregnant
A negative test result on file from her primary care physician
A negative urine pregnancy test performed any time in the prior month

Correct answer: A negative serum or urine pregnancy test within the timeframe specified in the protocol

Protocols involving teratogenic agents require a documented negative pregnancy test within the protocol-specified window (typically 24-72 hours before enrollment) to confirm eligibility.

Question 15: A randomized controlled trial uses a PROBE design. What does PROBE stand for?

Prospective Randomized Outcome-Based Evaluation
Placebo-controlled Randomized Observational Blinded Evaluation
Parallel Randomized Open-label Blinded Efficacy
Prospective Randomized Open Blinded End-point (Correct answer)

Correct answer: Prospective Randomized Open Blinded End-point

PROBE (Prospective Randomized Open Blinded End-point) uses open-label treatment assignment but blinded endpoint assessment to reduce bias.

Question 16: A clinical site is closing and the principal investigator is leaving the institution. Regarding trial records, the investigator must:

Destroy identifiable records to protect subject privacy
Take all records to their new institution without notifying the sponsor
Notify the sponsor and arrange for appropriate transfer or storage of records per regulatory and sponsor requirements (Correct answer)
Transfer records only if the IRB approves the move

Correct answer: Notify the sponsor and arrange for appropriate transfer or storage of records per regulatory and sponsor requirements

When a site closes or an investigator leaves, the sponsor must be notified and records must be transferred or stored according to regulatory and sponsor requirements to maintain their integrity.

Question 17: A protocol mandates collection of concomitant medications at every study visit. A subject starts a new over-the-counter NSAID between visits. When should this be documented?

Only at the next scheduled visit
At study completion during the end-of-study assessment
Only if the subject reports side effects
At the earliest opportunity, such as a phone call or unscheduled visit (Correct answer)

Correct answer: At the earliest opportunity, such as a phone call or unscheduled visit

Concomitant medications should be documented as soon as they are reported to ensure accurate safety data capture and assessment of potential protocol deviations.

Question 18: In a clinical trial, a 'surrogate endpoint' is best described as:

A patient-reported quality-of-life measure
The primary clinical outcome of interest (e.g., mortality)
A biomarker intended to predict a clinical outcome (Correct answer)
An exploratory safety measure

Correct answer: A biomarker intended to predict a clinical outcome

Surrogate endpoints are biomarkers (e.g., HbA1c, tumor size) used as stand-ins for clinical outcomes, assumed to predict them.

Question 19: At what reading level should informed consent documents ideally be written, per FDA and OHRP guidance?

10th grade
8th grade or below (Correct answer)
Graduate level for complex medical studies
College level (12th grade)

Correct answer: 8th grade or below

FDA and OHRP recommend consent documents be written at an 8th-grade reading level or below to ensure comprehension across diverse subject populations.

Question 20: What is MedWatch, and when is it used in the context of clinical research?

A real-time patient monitoring app used during clinical trials
The FDA's safety reporting program for reporting serious problems with human medical products (Correct answer)
A regulatory database for tracking IND submissions
A consent monitoring tool used by IRBs

Correct answer: The FDA's safety reporting program for reporting serious problems with human medical products

MedWatch is the FDA's Safety Reporting Program, used to report serious adverse events, product quality problems, and medication errors involving FDA-regulated products.

Question 21: During a monitoring visit, a sponsor's clinical research associate (CRA) finds undocumented protocol deviations that may have affected participant safety. What is the MOST appropriate next step?

Ignore minor deviations that did not result in harm
Immediately terminate the site without further review
Document the findings in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPAs) (Correct answer)
Correct the records retroactively without informing the IRB

Correct answer: Document the findings in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPAs)

Monitoring findings must be documented and addressed through formal CAPA processes to correct deficiencies and prevent recurrence.

Question 22: A participant who was lost to follow-up contacts the site reporting a hospitalization that occurred two months ago. The investigator should:

Ignore the event because it was not reported within the protocol's SAE window
Report it only to the sponsor but not to the IRB since it is retrospective
Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria (Correct answer)
Reopen the participant's case only if the event was fatal

Correct answer: Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria

Retrospective SAE reports must still be assessed, documented, and reported if they meet SAE criteria; there is no regulatory exemption for late discovery.

Question 23: A participant withdraws consent mid-trial citing discomfort with study procedures. What is the investigator's responsibility regarding safety follow-up?

Offer appropriate medical follow-up for any ongoing safety concerns, with the participant's agreement (Correct answer)
Transfer responsibility entirely to the participant's personal physician with no further contact
No follow-up is required once consent is withdrawn
Continue study assessments regardless of withdrawal

Correct answer: Offer appropriate medical follow-up for any ongoing safety concerns, with the participant's agreement

Even after withdrawal, investigators should offer safety follow-up for any ongoing adverse events, respecting the participant's autonomy while protecting their welfare.

Question 24: A clinical trial uses an electronic data capture (EDC) system. Which feature of EDC best supports data integrity?

Allowing investigators to edit any field at any time without tracking
Disabling query generation to reduce workload
Built-in edit checks and audit trails that record all changes (Correct answer)
Storing data locally on site computers without backup

Correct answer: Built-in edit checks and audit trails that record all changes

EDC systems with edit checks and comprehensive audit trails ensure data accuracy, completeness, and traceability per ALCOA+ principles.

Question 25: What is scope creep in CPI project management?

Incremental feature addition technique
Uncontrolled scope expansion without adjusting time, cost, or resources (Correct answer)
Reducing deliverables
Natural planned growth

Correct answer: Uncontrolled scope expansion without adjusting time, cost, or resources

Scope creep adds requirements without formal evaluation, causing schedule delays and budget overruns.

Question 26: What is document version control in CPI?

No change tracking
Tracking changes, identifying current versions, and maintaining history (Correct answer)
Same names for all files
Printing every draft

Correct answer: Tracking changes, identifying current versions, and maintaining history

Version control tracks revisions, identifies current versions, and maintains change history to ensure document integrity.

Question 27: Under 21 CFR 312.62, how long must investigators retain study records after the investigation is discontinued or completed, or FDA notifies the investigator the IND application is no longer in effect?

1 year
2 years (Correct answer)
5 years
10 years

Correct answer: 2 years

21 CFR 312.62 requires investigators to retain study records for 2 years after the investigation is discontinued or completed, or after FDA notice that the IND is no longer in effect.

Question 28: A clinical trial site has identified a Clostridioides difficile (C. diff) infection in a participant. Which disinfectant is REQUIRED to decontaminate the environment?

Hydrogen peroxide vapor (standard concentration)
Sodium hypochlorite (bleach) solution (Correct answer)
Quaternary ammonium compound
Alcohol-based hand rub

Correct answer: Sodium hypochlorite (bleach) solution

C. difficile spores are resistant to alcohol and many disinfectants; sodium hypochlorite (bleach) is required for effective environmental decontamination.

Question 29: What is the purpose of data collection in clinical research?

To gather and analyze information for evaluating treatments (Correct answer)
To recruit participants
To monitor patient progress
To monitor side effects

Correct answer: To gather and analyze information for evaluating treatments

Data collection is the systematic process of acquiring relevant information in clinical research to address the study's objectives. This data is then rigorously analyzed to evaluate the safety and efficacy of new treatments or interventions, ultimately informing medical practice and patient care.

Question 30: A CPI is reviewing a research proposal that offers $500 per visit to participants in a 10-visit study. Which ethical concern is MOST relevant?

The total payment exceeds the IRB's standard reimbursement cap
Monetary payment is only permissible for Phase III and IV trials
FDA regulations prohibit monetary compensation in clinical trials
Excessive payment may constitute undue inducement, compromising voluntariness of consent (Correct answer)

Correct answer: Excessive payment may constitute undue inducement, compromising voluntariness of consent

Undue inducement occurs when payment is so large that it compromises participants' ability to freely weigh risks and benefits, threatening the voluntariness of consent.

Question 31: A protocol amendment changes the primary endpoint of an ongoing clinical trial. What is the MOST important immediate action the investigator must take?

Implement the change immediately to avoid protocol deviations
Notify all currently enrolled subjects and obtain updated consent before continuing
Continue the trial and apply the change at next patient visit
Submit the amendment to the IRB and obtain approval before implementing (Correct answer)

Correct answer: Submit the amendment to the IRB and obtain approval before implementing

Protocol amendments that alter primary endpoints require IRB review and approval before implementation.

Question 32: A subject reports taking St. John's Wort herbal supplement daily. Why is this significant during patient assessment in a clinical trial?

It only matters if the subject is also taking anticoagulants
Herbal supplements require IRB approval before they can be taken on trial
St. John's Wort is a potent CYP3A4 inducer that can alter investigational drug metabolism (Correct answer)
It is not significant because herbal supplements are not medications

Correct answer: St. John's Wort is a potent CYP3A4 inducer that can alter investigational drug metabolism

St. John's Wort strongly induces CYP3A4 enzymes, which can significantly reduce plasma levels of many investigational drugs and compromise efficacy or safety assessments.

Question 33: What are Good Clinical Practice (GCP) guidelines?

A method of recruiting participants
A study design protocol
Guidelines for ethical and scientific conduct in clinical trials (Correct answer)
A process for drug approval

Correct answer: Guidelines for ethical and scientific conduct in clinical trials

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human subjects. Adherence to GCP ensures the protection of the rights, safety, and well-being of trial participants, and that the data collected are credible and accurate. These guidelines are fundamental for the integrity and validity of clinical research.

Question 34: An investigator conducting a vaccine trial must report a cluster of injection-site abscesses in participants. This is BEST classified as a:

Serious adverse event requiring expedited reporting (Correct answer)
Protocol deviation
Minor adverse event documentable in routine reports
Site infection control failure requiring OSHA notification

Correct answer: Serious adverse event requiring expedited reporting

A cluster of injection-site abscesses is a serious adverse event potentially linked to the investigational product or technique and requires expedited reporting.

Question 35: A Phase II dose-ranging trial uses an adaptive design to modify doses based on interim safety data. Which regulatory principle must be maintained to preserve trial integrity?

Pre-specified adaptation rules and maintenance of blinding (Correct answer)
Unblinded interim analyses by the sponsor's study team
Post-hoc determination of dose adjustments by the investigator
No IRB notification is required for pre-planned adaptations

Correct answer: Pre-specified adaptation rules and maintenance of blinding

Adaptive designs must have pre-specified decision rules in the protocol; unplanned adaptations or unblinding of the sponsor team inflate type I error and compromise regulatory acceptability.

Question 36: A study drug is administered as a prodrug that requires hepatic conversion to its active metabolite. A participant with Child-Pugh Class C cirrhosis enrolls. What is the primary concern?

Enhanced prodrug activation causing toxicity
Increased renal clearance of the active metabolite
No effect as prodrugs bypass hepatic metabolism
Impaired prodrug activation leading to reduced efficacy (Correct answer)

Correct answer: Impaired prodrug activation leading to reduced efficacy

Severe hepatic impairment reduces the enzymatic capacity to convert prodrugs to active forms, potentially rendering the drug ineffective in participants with Child-Pugh C cirrhosis.

Question 37: A sponsor issues an urgent safety communication notifying investigators of a new contraindication discovered during a trial. The investigator's FIRST action should be:

Review currently enrolled participants for the contraindication and take protective action immediately (Correct answer)
Await FDA guidance before acting on the sponsor's communication
Discuss the communication at the next investigator meeting
Notify the IRB and wait for approval before reviewing participant records

Correct answer: Review currently enrolled participants for the contraindication and take protective action immediately

Upon receipt of urgent safety communications, investigators must immediately assess enrolled participants for risk and take protective action without delay.

Question 38: What is evidence-based practice in CPI Pharmacology & Medication Management?

Integrating research evidence with expertise and client needs (Correct answer)
Doing whatever clients request
Using newest unproven methods
Following intuition only

Correct answer: Integrating research evidence with expertise and client needs

Evidence-based practice combines research, expertise, and client preferences for optimal outcomes.

Question 39: What is the importance of continuing education for CPI professionals in Pharmacology & Medication Management?

Justifying higher fees
Maintaining current knowledge and adapting to industry changes (Correct answer)
Filling time between engagements
Only for new professionals

Correct answer: Maintaining current knowledge and adapting to industry changes

Continuing education keeps professionals current with developments and best practices while meeting certification requirements.

Question 40: A participant taking a study SSRI develops hyperthermia, clonus, agitation, and diaphoresis after self-medicating with tramadol. What is the most likely diagnosis?

Anticholinergic toxicity
Malignant hyperthermia
Serotonin syndrome (Correct answer)
Neuroleptic malignant syndrome

Correct answer: Serotonin syndrome

Tramadol inhibits serotonin reuptake; combined with an SSRI, excess serotonergic activity causes serotonin syndrome characterized by the triad of mental status changes, autonomic instability, and neuromuscular abnormalities.

Question 41: When a protocol includes an 'interim analysis,' what is the primary risk that must be managed?

Inflation of Type I error (false positive) if proper alpha spending is not applied (Correct answer)
Loss of subject confidentiality during data review
Increased cost of the trial due to additional statistical testing
Delayed enrollment due to data lock requirements

Correct answer: Inflation of Type I error (false positive) if proper alpha spending is not applied

Interim analyses increase the chance of a false positive finding unless an alpha spending function (e.g., O'Brien-Fleming) is pre-specified to control Type I error.

Question 42: What is a 'protocol deviation' versus a 'protocol violation' in clinical research?

They are identical terms with no regulatory distinction
A violation is minor; a deviation is always serious
A deviation is an unplanned departure; a violation is a deviation that significantly affects participant safety or data integrity (Correct answer)
Deviations require IRB reporting; violations do not

Correct answer: A deviation is an unplanned departure; a violation is a deviation that significantly affects participant safety or data integrity

A protocol violation is a subset of deviations that significantly impacts participant rights, safety, or data integrity and typically requires expedited reporting.

Question 43: Under what circumstance may an investigator implement a protocol change without prior IRB approval?

When fewer than 10% of subjects are affected by the change
When the change is necessary to eliminate an immediate hazard to a research subject (Correct answer)
When the IRB has not responded within 30 days of the amendment submission
When the sponsor has approved the change in writing

Correct answer: When the change is necessary to eliminate an immediate hazard to a research subject

An investigator may implement a protocol change without prior IRB approval only when necessary to eliminate an immediate hazard to subjects, followed by prompt IRB notification.

Question 44: Which of the following BEST describes the concept of 'therapeutic misconception' in clinical research ethics?

An investigator's erroneous assumption that all research participants are cognitively capable of consent
The incorrect belief that placebos are always inert and cannot cause harm
A participant's false belief that research procedures are designed primarily for their individual therapeutic benefit rather than to generate generalizable knowledge (Correct answer)
The mistaken view that IRB approval guarantees that a study is safe for all participants

Correct answer: A participant's false belief that research procedures are designed primarily for their individual therapeutic benefit rather than to generate generalizable knowledge

Therapeutic misconception occurs when participants conflate clinical research with clinical care and believe research interventions are personalized to their medical benefit.

Question 45: A refrigerated investigational product requires storage at 2°C–8°C. The site refrigerator log shows a temperature excursion to 12°C for 4 hours. What is the most appropriate immediate action?

Continue dispensing since the excursion was brief
Re-cool the product and document the event in the next monitoring visit
Quarantine the affected product and notify the sponsor for disposition guidance (Correct answer)
Discard the product immediately without notification

Correct answer: Quarantine the affected product and notify the sponsor for disposition guidance

Temperature excursions require immediate quarantine of affected product and sponsor notification so the sponsor's quality team can evaluate stability data and provide disposition instructions.

Question 46: During a monitoring visit, the clinical research associate (CRA) finds that vital signs were not collected at a mandatory protocol visit for three subjects. As the investigator, what is the appropriate response?

Back-date the vital signs using the previous visit's values
Remove the affected visit data from the case report forms
Instruct staff to record 'not applicable' in the vital signs fields
Acknowledge the deviation, implement corrective actions, and complete a CAPA to prevent recurrence (Correct answer)

Correct answer: Acknowledge the deviation, implement corrective actions, and complete a CAPA to prevent recurrence

Missing mandatory assessments require acknowledgment as protocol deviations, documentation of corrective and preventive actions (CAPA), and implementation of process improvements to prevent recurrence.

Question 47: A clinical trial site is located in a region with endemic Coccidioidomycosis. Which infection prevention measure is MOST relevant for immunocompromised trial participants in this setting?

Testing all staff for coccidioidomycosis before site initiation
Recommending N95 masks for outdoor activities in dusty areas (Correct answer)
Administering prophylactic fluconazole to all participants
Requiring all participants to remain indoors

Correct answer: Recommending N95 masks for outdoor activities in dusty areas

In endemic areas, N95 masks during outdoor activity in dusty environments reduce inhalation of Coccidioides spores, particularly for immunocompromised individuals.

Question 48: An investigator wants to add a co-investigator to the study team mid-trial. What is required before this person can perform study tasks?

The co-investigator may begin immediately if they hold an active medical license
The sponsor must formally amend Form FDA 1572 before any tasks can be delegated
The co-investigator must be trained on the protocol, qualified for their delegated tasks, added to the delegation log, and the IRB notified per institutional requirements (Correct answer)
The co-investigator must complete a 30-day observation period before performing independent study tasks

Correct answer: The co-investigator must be trained on the protocol, qualified for their delegated tasks, added to the delegation log, and the IRB notified per institutional requirements

New study team members must receive protocol training, be qualified for their assigned tasks, be documented on the delegation log, and meet IRB notification requirements before performing study duties.

Question 49: What is the role of the principal investigator?

To recruit participants
To analyze the data
To oversee the research and ensure compliance with protocols (Correct answer)
To manage the budget

Correct answer: To oversee the research and ensure compliance with protocols

The Principal Investigator (PI) holds ultimate responsibility for the overall conduct of a clinical research study. This includes ensuring that the study adheres to the approved protocol, ethical guidelines, and regulatory requirements, as well as overseeing the research team and safeguarding participant welfare.

Question 50: A participant reveals during an emergency room visit that they are concurrently enrolled in another drug trial without the investigator's knowledge. The investigator should:

Immediately withdraw the participant and destroy their data
Take no action if the participant appears stable
Document the dual enrollment, assess safety risks, notify the IRB and sponsor, and determine eligibility impact (Correct answer)
Report the participant to the FDA for protocol violations

Correct answer: Document the dual enrollment, assess safety risks, notify the IRB and sponsor, and determine eligibility impact

Undisclosed dual enrollment is a protocol deviation that must be documented and reported; the investigator must assess potential drug interactions and inform oversight bodies.

Question 51: A subject reports a history of chronic kidney disease (CKD) Stage 3b. Which renal function test should the investigator prioritize to assess current eligibility against a protocol threshold?

24-hour urine protein collection only
Urinalysis with microscopy only
Renal ultrasound
Serum creatinine to calculate eGFR using CKD-EPI or Cockcroft-Gault (Correct answer)

Correct answer: Serum creatinine to calculate eGFR using CKD-EPI or Cockcroft-Gault

Serum creatinine-based eGFR calculation (CKD-EPI or Cockcroft-Gault) provides the quantitative renal function measure most protocols use to define eligibility thresholds.

Question 52: Which of the following actions by a clinical investigator constitutes scientific misconduct?

Enrolling a subject who later becomes non-compliant with study medication
Delegating phlebotomy to a qualified nurse
Contacting the IRB before the sponsor about a safety concern
Fabricating data in the case report form to fill in missed assessments (Correct answer)

Correct answer: Fabricating data in the case report form to fill in missed assessments

Fabricating or falsifying data in any research record is scientific misconduct and a serious regulatory violation subject to criminal penalties.

Question 53: A pharmacokinetic study measures drug concentrations at multiple time points. The AUC0-∞ is 1200 ng·h/mL and the AUC0-t is 1100 ng·h/mL. What does the residual AUC (100 ng·h/mL) represent?

Drug eliminated during the first-pass effect
The fraction of drug not bioavailable
Drug exposure extrapolated beyond the last measured time point to infinity (Correct answer)
Drug exposure during the absorption phase

Correct answer: Drug exposure extrapolated beyond the last measured time point to infinity

AUC0-∞ minus AUC0-t represents the extrapolated area from the last sampling time to infinity, estimated from the terminal elimination rate constant.

Question 54: An investigational product label for a US Phase II trial must include which of the following statements?

"Investigational Drug—Approved for Compassionate Use"
"Caution: New Drug—Limited by Federal Law to Investigational Use" (Correct answer)
"Approved by FDA for investigational use"
"For Clinical Trial Use Only—No Adverse Events Expected"

Correct answer: "Caution: New Drug—Limited by Federal Law to Investigational Use"

Per 21 CFR 312.6, investigational drug labels must bear the statement 'Caution: New Drug—Limited by Federal (or United States) law to investigational use' to clearly identify its investigational status.

Question 55: What is the key distinction between an 'adverse event' (AE) and an 'adverse drug reaction' (ADR)?

An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship to the study drug (Correct answer)
An AE occurs only in the treatment group; an ADR can occur in placebo groups
An AE requires FDA reporting; an ADR is reported only to the sponsor
An ADR must be serious; an AE can be of any severity

Correct answer: An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship to the study drug

An adverse event is any unfavorable occurrence during a study regardless of drug relationship, while an adverse drug reaction implies a reasonable causal relationship to the investigational product.

Question 56: When must a serious adverse event (SAE) be documented in the source record?

Within 30 days of occurrence
Only when the investigator determines it is study-related
At the next scheduled visit
As soon as it is identified or reported by the subject (Correct answer)

Correct answer: As soon as it is identified or reported by the subject

GCP requires contemporaneous documentation; SAEs must be recorded in the source record as soon as they are identified or reported.

Question 57: What must an investigator do when a research subject decides to withdraw from a study?

Require the subject to complete current study assessments before withdrawing
Honor the withdrawal immediately while asking if they consent to use previously collected data (Correct answer)
Require the subject to provide a written reason for withdrawal
Notify the FDA within 15 business days

Correct answer: Honor the withdrawal immediately while asking if they consent to use previously collected data

Investigators must respect a subject's right to withdraw at any time without penalty, and may ask—but not require—whether previously collected data may be retained for analysis.

Question 58: A clinical trial participant who is enrolled in a study on an experimental anticoagulant is scheduled for an elective dental procedure. What is the investigator's primary responsibility?

Coordinate communication between the dentist and the study team regarding investigational drug interactions (Correct answer)
Withdraw the participant from the study before the procedure
Refer the participant back to their primary care physician only
Suspend the investigational drug without informing the sponsor

Correct answer: Coordinate communication between the dentist and the study team regarding investigational drug interactions

The investigator must facilitate communication between treating providers to ensure safe management of concomitant procedures involving investigational agents.

Question 59: What is the role of the FDA in clinical trials?

To ensure safety and approval of new drugs (Correct answer)
To recruit participants
To monitor the progress of the trial
To test the drugs

Correct answer: To ensure safety and approval of new drugs

The U.S. Food and Drug Administration (FDA) is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. In clinical trials, the FDA reviews research protocols, monitors trial conduct, and ultimately decides whether new drugs or devices are safe and effective enough to be approved for public use. Their oversight is critical for patient protection and scientific integrity.

Question 60: Which of the following disinfection methods achieves the HIGHEST level of disinfection short of sterilization?

High-level disinfection with glutaraldehyde (Correct answer)
Low-level disinfection with quaternary ammonium compounds
Cleaning with detergent and water
Intermediate-level disinfection with isopropyl alcohol

Correct answer: High-level disinfection with glutaraldehyde

High-level disinfection with glutaraldehyde or other high-level disinfectants destroys all microorganisms except high numbers of bacterial spores.

Question 61: Which regulatory authority requires sponsors to submit a Development Safety Update Report (DSUR) for investigational drugs?

OHRP for federally funded investigations
FDA only, under 21 CFR 312
IRBs participating in multinational studies
ICH member authorities, per ICH E2F guideline (Correct answer)

Correct answer: ICH member authorities, per ICH E2F guideline

DSURs are required under ICH E2F by ICH member regulatory authorities (including FDA and EMA) as annual comprehensive safety updates for investigational drugs.

Question 62: A protocol requires that study drug be returned and accounted for at each visit. A subject arrives with an empty bottle but reports taking all doses as prescribed. The investigator should:

Report the missing drug to the DEA immediately
Document the subject's account, perform pill count of available materials, and record any discrepancy in the drug accountability log (Correct answer)
Discontinue the subject for inability to return unused medication
Accept the subject's statement and proceed without further documentation

Correct answer: Document the subject's account, perform pill count of available materials, and record any discrepancy in the drug accountability log

Drug accountability requires documentation of all discrepancies between dispensed and returned quantities, with the subject's explanation recorded.

Question 63: A participant in a Phase II oncology trial loses decision-making capacity mid-study after enrollment. What is the APPROPRIATE next step?

Continue the trial without any modification since consent was already obtained
Seek consent from a legally authorized representative (LAR) and assess whether continued participation is in the participant's best interest (Correct answer)
Withdraw the participant from the study immediately per regulatory mandate
Contact FDA for a waiver of continuing consent requirements

Correct answer: Seek consent from a legally authorized representative (LAR) and assess whether continued participation is in the participant's best interest

When a participant loses capacity, a LAR must provide permission for continued participation, and the investigator must assess whether continued participation benefits or harms the participant.

Question 64: Which of the following best describes the 'stopping rules' in a clinical trial protocol?

Sponsor authority to end the trial for business reasons
Predefined criteria that trigger immediate discontinuation of a participant or the entire trial (Correct answer)
Guidelines for when the IRB can revoke site approval
FDA-mandated timelines for IND withdrawal

Correct answer: Predefined criteria that trigger immediate discontinuation of a participant or the entire trial

Stopping rules are pre-specified safety thresholds in the protocol that mandate participant withdrawal or trial suspension when specific adverse events or data patterns occur.

Question 65: Protocol amendments that change study procedures must be reflected in the source documents by:

Retroactively updating all prior visit notes
Documenting the amendment approval date and updating procedures in subsequent visit notes (Correct answer)
Destroying prior records and re-documenting under the new protocol
No change to source documents is required for amendments

Correct answer: Documenting the amendment approval date and updating procedures in subsequent visit notes

Once an amendment is approved, subsequent documentation should reflect the updated procedures, noting the amendment effective date in the records.

Question 66: When conducting a clinical trial, what is the investigator's obligation regarding unanticipated problems involving risks to subjects or others?

Report promptly to the IRB, applicable regulatory authorities, and the sponsor per institutional policy (Correct answer)
Report to the sponsor only and allow the sponsor to notify the IRB
Document internally and report only if a subject experiences a related adverse event
Notify the FDA directly within 48 hours using Form MedWatch

Correct answer: Report promptly to the IRB, applicable regulatory authorities, and the sponsor per institutional policy

Unanticipated problems must be reported promptly to the IRB, sponsor, and applicable regulatory authorities per institutional and federal requirements.

Question 67: Under 21 CFR Part 312, what is the maximum timeframe within which an investigator must report an unexpected serious adverse event to the IRB?

Within 7 calendar days (Correct answer)
Within 10 working days
Within 30 days
Within 24 hours

Correct answer: Within 7 calendar days

Unexpected serious adverse events must be reported to the IRB within 7 calendar days under 21 CFR Part 312.

Question 68: A clinical trial participant becomes incapacitated mid-study and can no longer provide ongoing consent. The investigator should:

Discontinue all study procedures immediately without LAR consultation
Obtain consent from a legally authorized representative and reassess continued participation (Correct answer)
Continue study procedures as originally consented
Consult the IRB before taking any action

Correct answer: Obtain consent from a legally authorized representative and reassess continued participation

When a participant loses capacity, a legally authorized representative must be engaged to provide proxy consent before study procedures continue.

Question 69: Which regulatory pathway allows emergency use of an unapproved drug outside of a clinical trial when no alternatives exist?

Institutional emergency authorization under IRB guidelines
FDA Emergency Use Authorization under 21 CFR 601
Expanded access (compassionate use) under 21 CFR 312.310 (Correct answer)
Emergency IND waiver under 21 CFR 312.44

Correct answer: Expanded access (compassionate use) under 21 CFR 312.310

21 CFR 312.310 governs individual patient expanded access (compassionate use) for emergency situations where no alternatives are available.

Question 70: Under 21 CFR Part 312, which of the following adverse events requires expedited 15-day reporting by the sponsor to the FDA?

Protocol deviations that do not affect participant safety
All grade 1 or grade 2 adverse events
Any adverse event listed in the investigator's brochure
Unexpected serious adverse events that are reasonably related to the investigational drug (Correct answer)

Correct answer: Unexpected serious adverse events that are reasonably related to the investigational drug

Unexpected serious adverse drug reactions that may be causally related to the investigational product require expedited 15-day reporting to FDA under 21 CFR 312.32.

Question 71: A participant in an analgesic trial develops respiratory depression 6 hours after the last dose of the study opioid. The drug's half-life is 18 hours. What principle best explains this delayed toxicity?

Drug accumulation over multiple half-lives (Correct answer)
pH-dependent renal reabsorption
Enterohepatic recirculation
Active metabolite formation

Correct answer: Drug accumulation over multiple half-lives

Drugs with long half-lives accumulate with repeated dosing, reaching toxic concentrations only after several half-lives of administration.

Question 72: What should investigators do when they encounter an unanticipated problem during a study?

Continue the study as usual
Report the problem to authorities and assess risks (Correct answer)
Alter the study protocol without approval
Ignore the issue

Correct answer: Report the problem to authorities and assess risks

When an unanticipated problem arises during a study, it is crucial for investigators to promptly report it to the Institutional Review Board (IRB) or other relevant authorities. This ensures that the problem is thoroughly assessed for its impact on participant safety and the study's integrity, allowing for appropriate corrective actions to be taken.

Question 73: What is the difference between 'consent' and 'HIPAA authorization' in clinical research?

Consent covers participation in research procedures; HIPAA authorization covers use and disclosure of health information (Correct answer)
HIPAA authorization replaces consent for observational studies
Consent is optional; HIPAA authorization is always mandatory
They are identical documents that serve the same regulatory purpose

Correct answer: Consent covers participation in research procedures; HIPAA authorization covers use and disclosure of health information

Informed consent addresses a subject's agreement to participate in research activities, while HIPAA authorization specifically permits the researcher to access, use, and disclose protected health information.

Question 74: What is the primary role of a Data Safety Monitoring Board (DSMB) in a clinical trial?

To submit IND safety reports to the FDA on behalf of the investigator
To independently review accumulating safety data and recommend trial continuation, modification, or stopping (Correct answer)
To enroll subjects and collect case report forms
To audit the sponsor's financial reporting for the trial

Correct answer: To independently review accumulating safety data and recommend trial continuation, modification, or stopping

A DSMB is an independent committee that periodically reviews unblinded safety and efficacy data to protect subjects and ensure ongoing trial integrity.

Question 75: What is the purpose of maintaining a subject screening and enrollment log?

To track site staff training completion
To document all subjects screened, reasons for screen failures, and enrolled subject identifiers (Correct answer)
To list all adverse events reported during the trial
To record sponsor monitoring visit dates

Correct answer: To document all subjects screened, reasons for screen failures, and enrolled subject identifiers

Screening and enrollment logs document all subjects considered for the trial, screen failure reasons, and enrolled subject IDs to demonstrate recruitment transparency.

Question 76: Which statistical concept describes the probability of detecting a true treatment effect when one exists?

Confidence interval width
Type I error (alpha)
P-value threshold
Statistical power (1 – beta) (Correct answer)

Correct answer: Statistical power (1 – beta)

Statistical power is 1 minus the Type II error rate (beta) and represents the probability of correctly rejecting a false null hypothesis.

Question 77: Which element is NOT required in an investigator's SAE narrative report?

Participant's financial status and insurance coverage (Correct answer)
Treatment given and outcome of the event
Relevant medical history and concomitant medications
Temporal relationship between study drug and event

Correct answer: Participant's financial status and insurance coverage

SAE narratives require clinical details including timeline, medical history, concomitant medications, treatment, and outcome—financial or insurance details are irrelevant.

Question 78: In a protocol, the 'estimand' framework (ICH E9(R1)) defines which of the following?

The minimum detectable difference required for sample size calculation
The precise treatment effect to be estimated, including the target population, endpoint, and intercurrent event handling (Correct answer)
The statistical software to be used for primary analysis
The sequence of hypothesis testing for secondary endpoints

Correct answer: The precise treatment effect to be estimated, including the target population, endpoint, and intercurrent event handling

The estimand framework defines exactly what treatment effect is being estimated, including the population, endpoint, and how intercurrent events (like discontinuation) are handled.

Question 79: How does professional liability insurance protect CPI practitioners?

Covering disaster damage
Covering financial losses from claims of negligence or errors (Correct answer)
Paying health premiums
Protecting against equipment theft

Correct answer: Covering financial losses from claims of negligence or errors

This insurance covers financial consequences of claims alleging negligence or mistakes in professional services.

Question 80: An investigator receives a gift from a pharmaceutical company valued at $500 for speaking at a company-sponsored dinner. What is the most appropriate ethical action?

Accept it as standard compensation for physician time
Decline it only if it exceeds $1,000 in value
Disclose it to the institution and IRB per conflict-of-interest policies (Correct answer)
Report it solely to the IRS for tax purposes

Correct answer: Disclose it to the institution and IRB per conflict-of-interest policies

Financial relationships with sponsors, however small, must be disclosed per institutional conflict-of-interest policies to maintain research integrity.

Question 81: A subject enrolled in a clinical trial becomes pregnant during the study. What is the investigator's typical obligation?

Transfer care of the subject to an obstetrician with no further study involvement
Report only if a congenital anomaly is confirmed after delivery
Allow the subject to remain on study drug throughout the pregnancy
Follow the protocol's pregnancy management plan, which usually includes discontinuing the investigational product and reporting the pregnancy (Correct answer)

Correct answer: Follow the protocol's pregnancy management plan, which usually includes discontinuing the investigational product and reporting the pregnancy

Most protocols require investigational product discontinuation in pregnancy with follow-up reporting per the pregnancy management plan, as fetal risk is typically unknown.

Question 82: Which element of a patient's medical history is MOST critical to document during clinical trial screening to assess eligibility?

Chief complaint and reason for visit
All prior and concomitant medications, diagnoses, procedures, and allergies (Correct answer)
Social and family history only
Insurance and billing information

Correct answer: All prior and concomitant medications, diagnoses, procedures, and allergies

A complete medical history including all prior/concomitant medications, diagnoses, procedures, and allergies is essential to evaluate inclusion/exclusion criteria and potential drug interactions.

Question 83: A Data Safety Monitoring Board (DSMB) recommends immediate trial suspension due to a safety signal. The investigator's responsibility is to:

Continue only with participants already enrolled but stop new enrollment
Immediately halt enrollment and notify all participants currently on study drug (Correct answer)
Await IRB confirmation before stopping any study activities
Continue enrolling until the sponsor issues an official stop order

Correct answer: Immediately halt enrollment and notify all participants currently on study drug

Upon a DSMB safety-based suspension recommendation communicated through the sponsor, investigators must immediately halt enrollment and take steps to protect current participants.

Question 84: What is the first step in CPI risk assessment?

Purchasing insurance
Identifying potential hazards and threats (Correct answer)
Assigning blame
Ignoring minor risks

Correct answer: Identifying potential hazards and threats

Risk assessment begins with systematic identification of all potential hazards, forming the foundation for all subsequent analysis.

Question 85: A physician investigator notices that laboratory values collected at one site are consistently 10% higher than other sites. This is an example of:

Random error
Type II error
Sampling variability
Systematic bias (Correct answer)

Correct answer: Systematic bias

Consistent directional differences across a site indicate systematic bias, often due to equipment calibration or procedural differences.

Question 86: Which allocation concealment method best prevents selection bias in an RCT?

Centralized randomization via a telephone or web system (Correct answer)
Assignment based on date of birth
Sealed opaque envelopes prepared by the investigator
Alternating assignment (every other patient)

Correct answer: Centralized randomization via a telephone or web system

Centralized randomization systems are inaccessible to enrolling investigators, providing the strongest protection against selection bias.

Question 87: How should an investigator properly document an adverse event in a Case Report Form (CRF)?

Enter only SAEs; non-serious AEs are tracked informally in site notes
Document all AEs with onset date, duration, severity, relationship to study drug, action taken, and outcome (Correct answer)
Record only events the investigator believes are drug-related
Use standard ICD-10 diagnosis codes exclusively without narrative description

Correct answer: Document all AEs with onset date, duration, severity, relationship to study drug, action taken, and outcome

Complete AE documentation in a CRF requires recording onset date, duration, severity grade, investigator's causality assessment, actions taken, and resolution or outcome.

Question 88: A protocol specifies that subjects must undergo a 'sentinel dosing' approach for the first cohort. This means:

All subjects in the cohort receive study drug simultaneously to maximize data collection
Subjects are randomized in pairs to compare active drug versus placebo
One or two subjects are dosed first and observed for safety before dosing the remaining cohort (Correct answer)
A sentinel physician reviews all adverse events before treatment proceeds

Correct answer: One or two subjects are dosed first and observed for safety before dosing the remaining cohort

Sentinel dosing exposes one or two subjects first to identify early safety signals before the remaining cohort is dosed.

Question 89: An investigator discovers a protocol deviation occurred during an emergency—study drug was given outside the dosing window to stabilize a participant. This should be:

Corrected by adjusting the next scheduled dose without documentation
Documented and reported to the IRB and sponsor per protocol deviation procedures (Correct answer)
Not reported because the deviation was medically justified
Reported only to the sponsor, not the IRB

Correct answer: Documented and reported to the IRB and sponsor per protocol deviation procedures

All protocol deviations, including those made for emergency medical reasons, must be documented and reported to both the IRB and sponsor.

Question 90: During a trial, a participant is found to have taken a prohibited concomitant medication (a CYP3A4 inducer) for 2 weeks. The study drug is a CYP3A4 substrate. What is the most likely effect on efficacy assessments?

Increased study drug bioavailability
Increased study drug exposure leading to overestimation of toxicity
No effect as CYP induction only affects metabolism of the inducer
Reduced study drug exposure leading to potential underestimation of efficacy (Correct answer)

Correct answer: Reduced study drug exposure leading to potential underestimation of efficacy

CYP3A4 induction accelerates metabolism of CYP3A4 substrates, lowering their AUC and potentially causing falsely negative efficacy results.

Question 91: An investigational monoclonal antibody has a volume of distribution (Vd) of 4 L in a 70 kg participant. What does this indicate about the drug's distribution?

The drug is primarily stored in adipose tissue
The drug is largely confined to plasma and does not distribute into tissues (Correct answer)
The drug extensively distributes into peripheral tissues
The drug crosses the blood-brain barrier efficiently

Correct answer: The drug is largely confined to plasma and does not distribute into tissues

A Vd of approximately 4 L approximates plasma volume, indicating that large molecules like monoclonal antibodies remain predominantly in the vascular compartment due to their size.

Question 92: In clinical trial statistics, a p-value of 0.03 means:

There is a 3% probability that the null hypothesis is true
There is a 3% probability of observing results at least as extreme as those obtained, assuming the null hypothesis is true (Correct answer)
The study has 97% power to detect the effect
The treatment effect is clinically meaningful

Correct answer: There is a 3% probability of observing results at least as extreme as those obtained, assuming the null hypothesis is true

A p-value quantifies the probability of obtaining the observed (or more extreme) results under the null hypothesis; it does not directly state the probability that the null hypothesis is true.

Question 93: A protocol specifies treatment until 'disease progression or unacceptable toxicity.' A subject's imaging shows stable disease but the subject reports significantly worsening quality of life. Should the investigator discontinue treatment?

Yes, if the deterioration meets the protocol's definition of 'unacceptable toxicity' or falls under investigator clinical judgment criteria (Correct answer)
No, because stable disease means the subject must continue per protocol
Yes, because any subject complaint requires immediate treatment discontinuation
No, because quality of life is not a valid reason to discontinue treatment in a clinical trial

Correct answer: Yes, if the deterioration meets the protocol's definition of 'unacceptable toxicity' or falls under investigator clinical judgment criteria

Significant quality of life deterioration may meet protocol-defined unacceptable toxicity criteria or fall within the investigator's discretion to discontinue in the subject's best interest.

Question 94: A CPI learns that a colleague has fabricated patient data in a clinical trial. What is the most appropriate immediate action?

Report the misconduct to the IRB, sponsor, and relevant institutional authorities (Correct answer)
Withdraw from the trial without informing anyone to avoid conflict
Confront the colleague privately and give them time to self-correct
Ignore it if the overall study data appear valid

Correct answer: Report the misconduct to the IRB, sponsor, and relevant institutional authorities

Research misconduct must be reported to protect participants and the integrity of science; self-correction by the offending party is insufficient.

Question 95: The Nuremberg Code, as a foundational document in research ethics, established which paramount requirement for human research?

Governmental oversight of all research involving more than 50 participants
The voluntary consent of the human subject is absolutely essential (Correct answer)
Mandatory independent scientific peer review before any human study begins
A maximum of 3 years for any single clinical investigation

Correct answer: The voluntary consent of the human subject is absolutely essential

The first and most important principle of the Nuremberg Code is that voluntary consent of the human subject is absolutely essential to ethical research.

Question 96: Which federal office is responsible for overseeing human research protections, including informed consent compliance?

NIH Office of Research Integrity (ORI)
FDA Center for Drug Evaluation and Research (CDER)
Office for Human Research Protections (OHRP) (Correct answer)
CMS Center for Clinical Standards

Correct answer: Office for Human Research Protections (OHRP)

OHRP oversees compliance with the Common Rule (45 CFR Part 46) and is the primary federal office responsible for protecting human research subjects.

Question 97: Who is primarily responsible for reporting SAEs to the clinical trial sponsor?

The Data Safety Monitoring Board
The principal investigator or sub-investigator at the site (Correct answer)
The FDA district office
The IRB chairperson

Correct answer: The principal investigator or sub-investigator at the site

The principal investigator is responsible for promptly reporting all SAEs to the sponsor, who then evaluates and submits required safety reports to the FDA.

Question 98: When a clinical trial is terminated early, which statement regarding investigational product management is correct?

Only IP dispensed to subjects requires accountability; remaining stock can be discarded without documentation
The investigator may retain unused IP for future investigational use without sponsor approval
Drug accountability records can be destroyed immediately once the termination notice is signed
IP reconciliation and final disposition (return or destruction per sponsor instructions) must be completed even though the trial ended early (Correct answer)

Correct answer: IP reconciliation and final disposition (return or destruction per sponsor instructions) must be completed even though the trial ended early

Early termination does not eliminate drug accountability obligations; all IP—dispensed, returned by subjects, and remaining in inventory—must be fully reconciled and disposed of per sponsor instructions with complete documentation.

Question 99: What is the key difference between a 'protocol deviation' and a 'protocol violation' in clinical research?

Violations are reported to the FDA; deviations are reported only to the sponsor
A deviation affects eligibility criteria; a violation affects study procedures
A deviation is a minor unplanned departure; a violation is a significant departure that may affect subject safety or data integrity (Correct answer)
A deviation is intentional; a violation is unintentional

Correct answer: A deviation is a minor unplanned departure; a violation is a significant departure that may affect subject safety or data integrity

A protocol deviation is a minor unplanned departure from the approved protocol, while a protocol violation is a significant departure that may impact subject safety, rights, or the integrity of study data.

Question 100: A trial protocol requires participant fasting for 10 hours before each dose of an oral study drug. A participant reports eating a high-fat meal 2 hours before dosing. What pharmacokinetic parameters are most likely affected?

Volume of distribution decreased due to food-induced protein displacement
Renal clearance increased due to increased blood flow
Elimination half-life shortened due to food-induced enzyme induction
Tmax delayed and Cmax altered due to slower gastric emptying with food (Correct answer)

Correct answer: Tmax delayed and Cmax altered due to slower gastric emptying with food

High-fat meals delay gastric emptying, slowing drug absorption and delaying Tmax; Cmax and AUC may increase or decrease depending on whether the drug has enhanced or reduced absorption with food.

Question 101: Under 21 CFR Part 312, how long must investigators retain clinical trial records after the investigation is discontinued or completed?

5 years
2 years
10 years
At least 2 years following the date a marketing application is approved, or 2 years after the investigation is discontinued (Correct answer)

Correct answer: At least 2 years following the date a marketing application is approved, or 2 years after the investigation is discontinued

21 CFR 312.62 requires investigators to retain records for at least 2 years after approval of a marketing application or 2 years after discontinuation of the investigation.

Question 102: When a protocol specifies 'individualized dose titration,' what principle distinguishes this from fixed-dose protocols?

Doses are adjusted based on individual subject response, tolerability, or biomarker levels within protocol-defined limits (Correct answer)
The investigator freely prescribes any dose without protocol constraints
Dose selection is based solely on the subject's body weight
All subjects receive identical doses to ensure comparability of data

Correct answer: Doses are adjusted based on individual subject response, tolerability, or biomarker levels within protocol-defined limits

Individualized dose titration adjusts doses for each subject based on defined criteria such as response or toxicity, within protocol-specified minimum and maximum limits.

Question 103: Which failure mode is MOST commonly identified in clinical trials through a Failure Mode and Effects Analysis (FMEA)?

Process steps that could lead to participant harm if they fail (Correct answer)
Investigator fee payment delays
Insufficient randomization block sizes
Sponsor budget overruns

Correct answer: Process steps that could lead to participant harm if they fail

FMEA proactively identifies process steps where failure could harm participants, allowing risk mitigation before the trial begins.

Question 104: What is the purpose of randomization in clinical trials?

To speed up recruitment
To avoid bias and ensure comparable groups (Correct answer)
To increase the number of participants
To make treatment choices random

Correct answer: To avoid bias and ensure comparable groups

The purpose of randomization in clinical trials is to avoid bias and ensure that the treatment groups are comparable in terms of both known and unknown confounding factors. By assigning participants to groups purely by chance, randomization helps distribute characteristics evenly across groups. This allows researchers to confidently attribute any observed differences in outcomes to the intervention being studied, rather than to pre-existing differences between the groups.

Question 105: The ALCOA principle in clinical data documentation stands for:

Auditable, Logical, Consistent, Objective, Accountable
Attributable, Legible, Contemporaneous, Original, Accurate (Correct answer)
Accurate, Legible, Contemporaneous, Original, Attributable
Accountable, Linked, Complete, Organized, Auditable

Correct answer: Attributable, Legible, Contemporaneous, Original, Accurate

ALCOA stands for Attributable, Legible, Contemporaneous, Original, and Accurate — the five core data quality standards in GCP.

Question 106: In risk management for clinical research, what does 'residual risk' mean?

The level of risk that remains after all risk mitigation measures have been implemented (Correct answer)
The risk accepted by the sponsor on behalf of the investigator
Risk that has been completely eliminated by safety controls
Risk recorded in the protocol but not yet evaluated

Correct answer: The level of risk that remains after all risk mitigation measures have been implemented

Residual risk is the remaining risk after controls are applied; it must be acceptable relative to anticipated benefits for the trial to proceed.

Question 107: Which of the following is a key advantage of an adaptive trial design over a traditional fixed design?

Adaptive trials always produce larger effect size estimates
Adaptive designs eliminate the need for IRB oversight
Adaptive designs do not require a statistical analysis plan
Pre-specified modifications to the trial (e.g., sample size, dose) can be made based on interim data without inflating Type I error (Correct answer)

Correct answer: Pre-specified modifications to the trial (e.g., sample size, dose) can be made based on interim data without inflating Type I error

Adaptive designs allow pre-planned modifications using interim data while controlling Type I error through appropriate statistical methods, increasing efficiency.

Question 108: What is a needs assessment in CPI Pharmacology & Medication Management practice?

Office supply list
Property appraisal
Benefits survey
Identifying gaps between current conditions and desired outcomes (Correct answer)

Correct answer: Identifying gaps between current conditions and desired outcomes

A needs assessment identifies gaps between current performance and desired outcomes to justify improvements.

Question 109: Which core element must be included in ALL informed consent documents under 21 CFR 50.25?

A statement that participation is voluntary and refusal involves no penalty (Correct answer)
The sponsor's financial interest in the study outcome
A list of all co-investigators
The investigator's curriculum vitae

Correct answer: A statement that participation is voluntary and refusal involves no penalty

A statement confirming that participation is voluntary and that refusal or withdrawal carries no penalty or loss of benefits is a basic required element under 21 CFR 50.25.

Question 110: Which tool is commonly used to screen for cognitive impairment and assess consent capacity in elderly clinical trial subjects?

Columbia Suicide Severity Rating Scale (C-SSRS)
Hamilton Anxiety Rating Scale (HAM-A)
Patient Health Questionnaire-9 (PHQ-9)
Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) (Correct answer)

Correct answer: Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA)

The MMSE and MoCA are validated cognitive screening tools used to identify cognitive impairment that may affect a subject's capacity to understand and consent to clinical trial participation.

Question 111: What is the importance of continuing education for CPI professionals in Infection Control & Prevention?

Justifying higher fees
Maintaining current knowledge and adapting to industry changes (Correct answer)
Only for new professionals
Filling time between engagements

Correct answer: Maintaining current knowledge and adapting to industry changes

Continuing education keeps professionals current with developments and best practices while meeting certification requirements.

Question 112: When a CRF field is left blank and no data were collected, what is the most appropriate action for the investigator?

Document the reason for missing data according to protocol and sponsor instructions (Correct answer)
Estimate the value based on previous visits
Leave it blank and move on
Enter 'N/A' without documentation

Correct answer: Document the reason for missing data according to protocol and sponsor instructions

Missing data must be documented with the reason according to protocol requirements; fabricating or estimating values without a pre-specified method is a GCP violation.

Question 113: The concept of 'therapeutic misconception' in clinical research refers to:

IRBs approving protocols without adequate risk review
Investigators using placebos without participant knowledge
Participants mistakenly believing that research procedures are designed primarily for their personal benefit (Correct answer)
Sponsors withholding trial results from regulators

Correct answer: Participants mistakenly believing that research procedures are designed primarily for their personal benefit

Therapeutic misconception occurs when participants conflate clinical care with research, undermining truly informed consent.

Question 114: What does the term 'imputation' refer to in clinical trial data analysis?

Removing outlier data points from the dataset
Recalculating endpoints after database lock
Converting continuous variables to categorical
Assigning values to missing data using statistical methods (Correct answer)

Correct answer: Assigning values to missing data using statistical methods

Imputation is the process of substituting estimated values for missing data to maintain dataset completeness and reduce bias.

Question 115: In a clinical trial, a participant develops a catheter-associated urinary tract infection (CAUTI). Which organism is most commonly implicated in CAUTIs?

Candida albicans
Escherichia coli (Correct answer)
Staphylococcus aureus
Pseudomonas aeruginosa

Correct answer: Escherichia coli

E. coli is the most common causative pathogen in catheter-associated urinary tract infections.

Question 116: RECIST 1.1 criteria for tumor response assessment classify a ≥30% decrease in the sum of diameters of target lesions as:

Stable Disease (SD)
Progressive Disease (PD)
Partial Response (PR) (Correct answer)
Complete Response (CR)

Correct answer: Partial Response (PR)

RECIST 1.1 defines Partial Response (PR) as at least a 30% decrease in the sum of diameters of target lesions compared to baseline.

Question 117: A participant in a drug trial develops an unexpected anaphylactic reaction. After stabilizing the patient, what is the FIRST documentation step the investigator should take?

Complete an SAE report form documenting the event details (Correct answer)
Notify the IRB before documenting in the source record
Update the protocol to exclude participants at risk
Wait for the event to resolve before documenting

Correct answer: Complete an SAE report form documenting the event details

Timely and accurate documentation in the SAE report form is the first required step after ensuring participant safety.

Question 118: A subject returns 4 of 10 dispensed tablets at the next visit. The diary shows 5 doses taken. What should the site do?

Document the discrepancy, query the subject about the missing tablet, and record the explanation in the accountability log (Correct answer)
Discontinue the subject from the trial immediately
Report a serious adverse event for medication misuse
Accept the return count and make no further inquiry

Correct answer: Document the discrepancy, query the subject about the missing tablet, and record the explanation in the accountability log

A count mismatch (10 dispensed − 5 taken = 5 expected returns, but only 4 returned) requires site staff to query the subject, document the explanation, and record everything in the accountability log to resolve the discrepancy.

Question 119: An emergency protocol amendment is submitted to the IRB to allow a new rescue medication. Under which condition may the investigator implement the amendment before IRB approval?

When the sponsor provides written authorization
Never; all amendments require prior IRB approval
When immediate use is necessary to eliminate apparent immediate hazard to participants (Correct answer)
When the amendment involves only minor procedural changes

Correct answer: When immediate use is necessary to eliminate apparent immediate hazard to participants

Under 21 CFR 56.108(a)(4), investigators may implement unapproved changes when necessary to eliminate an apparent immediate hazard, followed by prompt IRB notification.

Question 120: Which of the following is an example of information bias in clinical research?

Imbalanced baseline characteristics between groups
Systematic over-reporting of symptoms in one exposure group (Correct answer)
Differential loss to follow-up between treatment arms
Exclusion of non-English-speaking participants

Correct answer: Systematic over-reporting of symptoms in one exposure group

Information bias arises when data are collected or recorded differently across groups, such as when exposed participants are questioned more thoroughly about symptoms.

Question 121: The principal investigator delegates source document review and CRF completion to a sub-investigator. This delegation must be:

Re-delegated each calendar year regardless of staff changes
Documented on a delegation of authority log with the date and scope of delegation (Correct answer)
Verbally communicated to all site staff
Approved by the FDA before the sub-investigator may act

Correct answer: Documented on a delegation of authority log with the date and scope of delegation

All task delegations must be recorded on a delegation of authority log, specifying who is delegated, what tasks, and when the delegation begins and ends.

Question 122: Under the Common Rule (45 CFR 46), which population requires ADDITIONAL regulatory protections because they are considered 'vulnerable subjects'?

Healthy volunteers in Phase I pharmacokinetic studies
Healthcare workers participating in occupational health studies
Adults over age 65 enrolled in cardiovascular studies
Prisoners, pregnant women, and children (Correct answer)

Correct answer: Prisoners, pregnant women, and children

The Common Rule identifies prisoners (Subpart C), pregnant women/fetuses (Subpart B), and children (Subpart D) as vulnerable populations requiring additional protections.

Question 123: An investigator observes an unexpected cluster of similar adverse events among participants in the same treatment arm. What action should the investigator take FIRST?

Personally administer additional tests before informing anyone
Immediately report the potential safety signal to the sponsor and IRB for evaluation (Correct answer)
Dismiss the cluster as coincidental and continue the study
Await the next scheduled DSMB meeting to raise the concern

Correct answer: Immediately report the potential safety signal to the sponsor and IRB for evaluation

Clusters of similar adverse events may indicate a safety signal that requires prompt escalation to the sponsor and IRB for assessment.

Question 124: What is a near-miss report in CPI practice?

An employee near target
Documentation of an event that could have caused harm but did not (Correct answer)
A near break-even report
A project near deadline

Correct answer: Documentation of an event that could have caused harm but did not

Near-miss reports document events where harm almost occurred, providing data to prevent future incidents.

Question 125: When a serious adverse event (SAE) occurs during a clinical trial, the FDA requires the sponsor to submit an IND Safety Report within how many calendar days for unexpected fatal or life-threatening events?

30 days
24 hours
7 days (Correct answer)
15 days

Correct answer: 7 days

Under 21 CFR 312.32, unexpected fatal or life-threatening suspected adverse reactions must be reported to the FDA within 7 calendar days.

Certified Principal Investigator (CPI®)

The CPI® certification validates the expertise of physicians and advanced practice clinicians serving as principal investigators in clinical trials, covering GCP compliance, ethical conduct, site management, and data integrity across all phases of clinical research.

125

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds